Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly announces resignation of oncology head

Lilly announces resignation of oncology head

26th January 2011

Lilly has revealed that John Johnson, its senior vice-president and president of the Lilly Oncology division, is resigning from the company for personal and family reasons.

The former ImClone Systems chief executive officer (CEO) will leave Lilly on January 28th 2011 after originally joining the company in 2008, when the organisation completed its takeover of ImClone.

Mr Johnson has been credited with a key role in facilitating the acquisition, which was the largest in Lilly's history, and imClone's subsequent integration, as well as taking responsibility for leading Lilly's expanded oncology business since then.

The company stated that a successor to Mr Johnson will be announced in the coming weeks.

Dr John Lechleiter, president and CEO of Lilly, said: "He has always been a champion of serving patients and has guided the Lilly Oncology pipeline to an all-time high – one of the largest clinical-stage pipelines of potential cancer medicines in the industry."

Earlier this month, Lilly entered into a new collaboration with Boehringer Ingelheim that will see the two firms ally on research into new diabetes drugs.ADNFCR-8000103-ID-800365070-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.